Alkermes plc (NASDAQ:ALKS) Shares Sold by Amalgamated Bank

Amalgamated Bank decreased its stake in Alkermes plc (NASDAQ:ALKS) by 5.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 48,653 shares of the company’s stock after selling 2,934 shares during the period. Amalgamated Bank’s holdings in Alkermes were worth $1,362,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the stock. EFG Asset Management North America Corp. lifted its position in Alkermes by 0.5% in the second quarter. EFG Asset Management North America Corp. now owns 75,864 shares of the company’s stock valued at $1,828,000 after acquiring an additional 359 shares during the last quarter. United Services Automobile Association boosted its position in shares of Alkermes by 3.1% in the 2nd quarter. United Services Automobile Association now owns 13,208 shares of the company’s stock valued at $318,000 after purchasing an additional 400 shares during the period. Signaturefd LLC grew its stake in Alkermes by 51.2% during the 2nd quarter. Signaturefd LLC now owns 1,417 shares of the company’s stock worth $34,000 after buying an additional 480 shares during the last quarter. Handelsbanken Fonder AB increased its position in Alkermes by 0.3% during the third quarter. Handelsbanken Fonder AB now owns 220,600 shares of the company’s stock worth $6,175,000 after buying an additional 700 shares during the period. Finally, GAMMA Investing LLC lifted its stake in Alkermes by 44.4% in the second quarter. GAMMA Investing LLC now owns 2,287 shares of the company’s stock valued at $55,000 after buying an additional 703 shares during the last quarter. 95.21% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Cantor Fitzgerald lowered their target price on shares of Alkermes from $48.00 to $43.00 and set an “overweight” rating on the stock in a research report on Friday, October 25th. Robert W. Baird raised their price objective on shares of Alkermes from $37.00 to $38.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. Stifel Nicolaus raised shares of Alkermes from a “hold” rating to a “buy” rating and upped their target price for the company from $25.00 to $36.00 in a report on Tuesday, November 5th. StockNews.com raised Alkermes from a “hold” rating to a “buy” rating in a report on Sunday, July 28th. Finally, Mizuho upped their price objective on Alkermes from $35.00 to $40.00 and gave the company an “outperform” rating in a research note on Wednesday. One analyst has rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $35.42.

Insiders Place Their Bets

In related news, EVP Craig C. Hopkinson sold 58,996 shares of the firm’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $30.08, for a total value of $1,774,599.68. Following the completion of the sale, the executive vice president now owns 83,300 shares in the company, valued at $2,505,664. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, EVP Craig C. Hopkinson sold 58,996 shares of Alkermes stock in a transaction on Monday, November 11th. The stock was sold at an average price of $30.08, for a total transaction of $1,774,599.68. Following the completion of the transaction, the executive vice president now directly owns 83,300 shares of the company’s stock, valued at approximately $2,505,664. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Craig C. Hopkinson sold 10,471 shares of the company’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $29.53, for a total value of $309,208.63. Following the completion of the sale, the executive vice president now directly owns 99,238 shares in the company, valued at $2,930,498.14. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 4.89% of the stock is currently owned by company insiders.

Alkermes Stock Up 0.0 %

ALKS opened at $29.24 on Thursday. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.45 and a quick ratio of 3.03. Alkermes plc has a 12 month low of $22.06 and a 12 month high of $32.88. The stock has a market capitalization of $4.73 billion, a P/E ratio of 14.99, a P/E/G ratio of 0.98 and a beta of 0.47. The business has a 50 day simple moving average of $27.71 and a 200-day simple moving average of $26.16.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.